E.E. Stobberingh

1.4k total citations
50 papers, 960 citations indexed

About

E.E. Stobberingh is a scholar working on Epidemiology, Applied Microbiology and Biotechnology and Molecular Medicine. According to data from OpenAlex, E.E. Stobberingh has authored 50 papers receiving a total of 960 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Epidemiology, 13 papers in Applied Microbiology and Biotechnology and 10 papers in Molecular Medicine. Recurrent topics in E.E. Stobberingh's work include Antibiotic Use and Resistance (13 papers), Urinary Tract Infections Management (11 papers) and Antibiotic Resistance in Bacteria (10 papers). E.E. Stobberingh is often cited by papers focused on Antibiotic Use and Resistance (13 papers), Urinary Tract Infections Management (11 papers) and Antibiotic Resistance in Bacteria (10 papers). E.E. Stobberingh collaborates with scholars based in Netherlands, Belgium and United Kingdom. E.E. Stobberingh's co-authors include A.I.M. Bartelds, S. Nys, A. van den Bogaard, Sandrine Gaillard, A. J. M. M. Beysens, Daisy Jonkers, N. London, C.H. Monfoort, J.S. Sussenbach and Tiny Van Merode and has published in prestigious journals such as The Lancet, Nucleic Acids Research and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

E.E. Stobberingh

44 papers receiving 871 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E.E. Stobberingh Netherlands 16 362 214 149 144 116 50 960
G. Aubert France 18 249 0.7× 148 0.7× 160 1.1× 247 1.7× 160 1.4× 53 1.0k
Maria Panopoulou Greece 16 267 0.7× 132 0.6× 119 0.8× 156 1.1× 144 1.2× 70 954
M. Rouveau France 13 333 0.9× 235 1.1× 108 0.7× 343 2.4× 162 1.4× 23 810
R.C. Spencer United Kingdom 18 467 1.3× 305 1.4× 114 0.8× 193 1.3× 212 1.8× 46 1.1k
Neriman Balaban Türkiye 17 337 0.9× 111 0.5× 82 0.6× 256 1.8× 204 1.8× 27 923
Frederic Gómez‐Bertomeu Spain 21 790 2.2× 246 1.1× 150 1.0× 152 1.1× 341 2.9× 73 1.6k
E. J. Vollaard Netherlands 13 155 0.4× 173 0.8× 225 1.5× 127 0.9× 271 2.3× 29 810
Helen Dedier Canada 11 177 0.5× 137 0.6× 157 1.1× 256 1.8× 328 2.8× 14 841
Paulo Pinto Gontijo Filho Brazil 24 219 0.6× 208 1.0× 215 1.4× 183 1.3× 481 4.1× 84 1.3k
Emily Sydnor United States 9 349 1.0× 106 0.5× 105 0.7× 104 0.7× 377 3.3× 11 919

Countries citing papers authored by E.E. Stobberingh

Since Specialization
Citations

This map shows the geographic impact of E.E. Stobberingh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E.E. Stobberingh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E.E. Stobberingh more than expected).

Fields of papers citing papers by E.E. Stobberingh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E.E. Stobberingh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E.E. Stobberingh. The network helps show where E.E. Stobberingh may publish in the future.

Co-authorship network of co-authors of E.E. Stobberingh

This figure shows the co-authorship network connecting the top 25 collaborators of E.E. Stobberingh. A scholar is included among the top collaborators of E.E. Stobberingh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E.E. Stobberingh. E.E. Stobberingh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Muller, Anouk E., et al.. (2023). Nitrofurantoin for the treatment of uncomplicated urinary tract infection in female patients: the impact of dosing regimen, age, and renal function on drug exposure. European Journal of Clinical Pharmacology. 79(8). 1043–1049. 2 indexed citations
2.
Wolffs, Petra, et al.. (2014). Impact of same-day antibiotic susceptibility testing on time to appropriate antibiotic treatment of patients with bacteraemia: a randomised controlled trial. European Journal of Clinical Microbiology & Infectious Diseases. 34(4). 831–838. 31 indexed citations
3.
Verbon, Annelies, et al.. (2010). Urinary Tract Infection in Male General Practice Patients: Uropathogens and Antibiotic Susceptibility. Urology. 76(2). 336–340. 32 indexed citations
4.
Stobberingh, E.E., et al.. (2009). Definition of infection in chronic wounds by Dutch nursing home physicians. International Wound Journal. 6(5). 404–404.
5.
Nys, S., Tiny Van Merode, A.I.M. Bartelds, & E.E. Stobberingh. (2006). Urinary tract infections in general practice patients: diagnostic tests versus bacteriological culture. Journal of Antimicrobial Chemotherapy. 57(5). 955–958. 68 indexed citations
6.
Gaillard, Sandrine, et al.. (2001). Prevention of Ventilator-associated Pneumonia by Oral Decontamination. American Journal of Respiratory and Critical Care Medicine. 164(3). 382–388. 205 indexed citations
7.
Kasteren, M.E.E. van, Inge C. Gyssens, Bart Jan Kullberg, et al.. (2000). [Optimizing antibiotics policy in the Netherlands. V. SWAB guidelines for perioperative antibiotic prophylaxis. Foundation Antibiotics Policy Team].. PubMed. 144(43). 2049–55. 27 indexed citations
8.
Maraha, B., et al.. (2000). Trends in antibiotic prescribing in general internal medicine wards: antibiotic use and indication for prescription. Clinical Microbiology and Infection. 6(1). 41–44. 3 indexed citations
9.
Sprenger, M, et al.. (1999). [European strategy for control of resistance to antibiotics].. PubMed. 143(25). 1322–5. 1 indexed citations
10.
Jonkers, Daisy, et al.. (1999). Antibacterial effect of garlic and omeprazole on Helicobacter pylori. Journal of Antimicrobial Chemotherapy. 43(6). 837–839. 82 indexed citations
11.
Kasteren, M.E.E. van, W. J. A. Wijnands, E.E. Stobberingh, R. Janknegt, & J.W.M. van der Meer. (1998). [Optimizing of antibiotics policy in the Netherlands. III. SWAB guidelines for antimicrobial therapy in adults hospitalized with bronchitis. Foundation Antibiotics Policy Work Group].. PubMed. 142(46). 2512–5. 3 indexed citations
12.
13.
London, N., et al.. (1996). In-vitro transfer of antibiotic resistance between faecal Escherichia coli strains isolated from pig farmers and pigs. Journal of Antimicrobial Chemotherapy. 37(6). 1141–1154. 15 indexed citations
14.
London, N., et al.. (1995). In-vivo transfer of resistance plasmids in rat, human or pig-derived intestinal flora using a rat model. Journal of Antimicrobial Chemotherapy. 36(6). 975–985. 16 indexed citations
15.
Stobberingh, E.E., D. M. MacLaren, & P.I.M. Schmitz. (1994). Comparative in-vitro activity of piperacillin-tazobactam against recent clinical isolates, a Dutch national multicentre study. Journal of Antimicrobial Chemotherapy. 34(5). 777–783. 5 indexed citations
16.
Janknegt, R., et al.. (1994). Antibiotic policies in Dutch hospitals for the treatment of patients with serious infection. Journal of Antimicrobial Chemotherapy. 34(6). 1059–1069. 2 indexed citations
17.
Janknegt, R., W. J. A. Wijnands, & E.E. Stobberingh. (1994). Antimicrobial prophylaxis in bowel surgery in the Netherlands. European Journal of Clinical Microbiology & Infectious Diseases. 13(7). 596–600. 6 indexed citations
18.
Stobberingh, E.E., et al.. (1993). Antibiotic guidelines and antibiotic utilization in Dutch hospitals. Journal of Antimicrobial Chemotherapy. 32(1). 153–161. 19 indexed citations
19.
Janknegt, Robert, et al.. (1993). Antimicrobial drug use in hospitals in the Netherlands, Germany and Belgium. European Journal of Clinical Microbiology & Infectious Diseases. 12(11). 832–838. 35 indexed citations
20.
Stobberingh, E.E., et al.. (1988). Inducing Capacity and Selection of Resistant Variants of Cefpirome (HR 810) in Comparison with Other β-Lactam Compounds. Chemotherapy. 34(6). 490–496. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Aubert Breakdown of academic impact, for papers by Maria Panopoulou Breakdown of academic impact, for papers by M. Rouveau Breakdown of academic impact, for papers by R.C. Spencer Breakdown of academic impact, for papers by Neriman Balaban Breakdown of academic impact, for papers by Frederic Gómez‐Bertomeu Breakdown of academic impact, for papers by E. J. Vollaard Breakdown of academic impact, for papers by Helen Dedier Breakdown of academic impact, for papers by Paulo Pinto Gontijo Filho Breakdown of academic impact, for papers by Emily Sydnor
Rankless by CCL
2026